Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03) (2021)
- Authors:
- Autor USP: CASTRO JUNIOR, GILBERTO DE - FM
- Unidade: FM
- DOI: 10.1177/17588359211022905
- Subjects: ESTUDOS PROSPECTIVOS; NEOPLASIAS PULMONARES (TERAPIA); SOBREVIVÊNCIA LIVRE DE DOENÇA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Therapeutic advances in medical oncology
- ISSN: 1758-8340
- Volume/Número/Paginação/Ano: v. 13, article ID 17588359211022900, 14p, 2021
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc
-
ABNT
GROSSI, Francesco et al. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). Therapeutic advances in medical oncology, v. 13, 2021Tradução . . Disponível em: https://doi.org/10.1177/17588359211022905. Acesso em: 01 out. 2024. -
APA
Grossi, F., Jaskiewicz, P., Ferreira, M., Czyzewicz, G., Kowalski, D., Ciuffreda, L., et al. (2021). Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). Therapeutic advances in medical oncology, 13. doi:10.1177/17588359211022905 -
NLM
Grossi F, Jaskiewicz P, Ferreira M, Czyzewicz G, Kowalski D, Ciuffreda L, Garcia-gomez R, Caruso S, Bosch-barrera J, Gautier S, Castro Junior G de C. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03) [Internet]. Therapeutic advances in medical oncology. 2021 ; 13[citado 2024 out. 01 ] Available from: https://doi.org/10.1177/17588359211022905 -
Vancouver
Grossi F, Jaskiewicz P, Ferreira M, Czyzewicz G, Kowalski D, Ciuffreda L, Garcia-gomez R, Caruso S, Bosch-barrera J, Gautier S, Castro Junior G de C. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03) [Internet]. Therapeutic advances in medical oncology. 2021 ; 13[citado 2024 out. 01 ] Available from: https://doi.org/10.1177/17588359211022905 - Diagnóstico de mutações ativadoras do gene EGFR em adenocarcinomas pulmonares: caracterização e implicações clínicas
- Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study
- Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
- Manual de oncologia torácica
- Lung Cancer in Brazil [Editorial]
- Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Noções de oncologia torácica
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score
Informações sobre o DOI: 10.1177/17588359211022905 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
